Does Mirena Affect Sex Drive? What the IUD Studies Actually Show

The question behind "mirena and sex drive" splits into two: did the device do it, and will it come back. The only pooled analysis built on progestin devices, Ghorbani and colleagues (2021), covering 19 studies and 710 women, found no significant change in sexual-function scores with the hormonal IUD through twelve months, and a positive change with the implant at six months. The broad contraception meta-analysis, Huang and colleagues (2020), 12 studies and 9,427 women, found a lower desire subscale at very high heterogeneity, with all methods pooled, mostly pills; that is an all-methods figure. In the ten-year phase 3 trial of the 52 milligram device, 1,714 women, desire or trouble finishing showed up in a small minority. The honest frame: the average barely moves, and some individuals do. The honest question is whether you are one of them.

Figures from Ghorbani et al. 2021 (PMID 32048542), Kerns et al. 2024 (PMID 38969201) and Huang et al. 2020 (PMID 32694069).

Is it the Mirena, or is it me?

When someone searches "mirena and sex drive", they are usually asking two things at once. Did the device do this, and is it coming back? Those are different questions, and the evidence treats them differently. On the first, the pooled numbers say the average woman's score barely moves. On the second, nobody can answer for you, because the data track groups, and a drop that shows up in one person does not have to show up in the average.

That is the frame worth holding onto: the average barely moves, and some individuals do. So the question is whether you are one of them, and what else changed around the same time as the insertion.

Name the trap plainly, because it is the one that misleads most. The broad 2020 meta-analysis pools every contraceptive method, mostly pills. Its desire figure is a contraception figure. It is not a Mirena figure. If you see that number attached to the IUD in other articles, do not read it that way.

The usual suspects move desire more than any device does. Stress is the big one, since a busy life raises cortisol and flattens wanting; stress, cortisol and sex drive covers that. Your cycle matters too, and desire naturally rises and falls across it; why sex drive comes and goes walks through the pattern. And if your wanting has always been responsive, building up after closeness and never arriving on its own, a new routine can make it feel absent when it is simply waiting; responsive versus spontaneous desire explains the difference.

The one analysis built on IUD and implant users

This is the only pooled analysis specific to progestin devices. Ghorbani and colleagues (2021) ran a systematic search of six databases up to December 2019, drew 5,244 articles in the primary search, and ended up with 19 studies meeting inclusion criteria, 710 women in total, mixing randomized controlled trials and before-after studies. They pooled the results with random-effects models and looked at sexual-function scores over time after insertion.

The results split cleanly. For the implant, there was no effect on sexual function three months after insertion (WMD 1.85; 95% CI -0.34 to 4.04; p = .098), and a positive effect at six months (WMD 3.48; 95% CI 2.78 to 4.19; p = .001). For the levonorgestrel IUS, the estimate ran at WMD 3.20 (95% CI -1.56 to 7.98; p = .188), meaning no significant change in female sexual function until twelve months after insertion. There was no evidence of publication bias. The IUD number comes with two caveats. The interval is wide and crosses zero, so the data are consistent with everything from a meaningful dip to a meaningful rise. And the pool mixes randomized and non-randomized before-after studies, which softens the certainty.

Read that third row slowly. A point estimate of 3.20 sounds like a gain, but the interval runs from -1.56 to 7.98, and the p value sits at .188. Twelve months of data, pooled across 19 studies, cannot show a change from before insertion. If your score dipped after insertion, the pooled evidence does not confirm that the device did it, and it does not rule it out either. That is why the cycle and day-to-day factors deserve a look before you blame the device; sex drive and your menstrual cycle covers the rhythm side, and low libido in women walks through the wider picture.

What the broad contraception meta-analysis found, and what it pooled

The bigger study is the one to be careful with. Huang and colleagues (2020) searched four databases up to December 2019 and pooled 12 studies, 7 cross-sectional, 3 cohorts and 1 case-control, 9,427 participants in total. Mean age among contraceptive users ran from 22.5 to 38.2 years. The pooled total FSFI came out at SMD -1.03 (95% CI -2.08 to 0.01, P = .053, I2 98.2%), and the pooled relative risk for a sexual problem sat at 1.29 (95% CI 0.72 to 2.28, P = .392, I2 76.0%). The one domain that cleared significance was the sexual-desire subscale, at SMD -1.17 (95% CI -2.09 to -0.24, P = .014, I2 97.7%). The remaining domain scores showed no significant differences.

The desire number comes with two caveats. The heterogeneity is very high, at I2 97.7%, which means the individual studies disagree widely and the pooled figure is a rough average over a spread. And the pool covers all contraceptive methods, mostly pills, with no IUD-specific subgroup reported. So the desire figure belongs to contraception as a category. It is never a Mirena figure, and treating it as one is how most people get this wrong. If your numbers are fine and you still feel flat, numbers fine, still flat is the place to start, because a lab result says nothing about desire.

A 2023 review, Ogle and colleagues, looked at copper and levonorgestrel IUDs specifically, drawing 35 quantitative papers rated against the STROBE statement. It found a positive impact of the hormonal IUD on sexual pain, a positive-to-neutral effect on desire, and generally non-impactful effects on the remaining domains. No pooled figures, percentages or sample sizes were reported, and the review covers mixed study quality, so it points in a direction without giving a size. The 2019 European position paper, Both and colleagues, is an expert consensus statement, and it says plainly that available evidence indicates a minority of women experience a change in general sexual response, desire, the finishing phase and relationship satisfaction, with mechanisms described as unclear. Consensus, in other words, agrees with the data: a minority, and no mechanism anyone can name.

Hormonal IUD, copper IUD, implant: the head-to-head cohorts

The cohorts that compare methods directly split both ways, which is exactly what you would expect when the average barely moves. Boozalis and colleagues (2016) ran a cross-sectional analysis of 1,938 of 9,256 Contraceptive CHOICE Project participants, who completed a baseline and a 6-month telephone survey. At six months after initiating a new method, 23.9% reported lacking interest in sex. Copper IUD users, the referent group, sat at 18.3%. Adjusted odds of lacking interest versus copper users: depot medroxyprogesterone 2.61 (95% CI 1.47 to 4.61), vaginal ring 2.53 (95% CI 1.37 to 4.69), implant 1.60 (95% CI 1.03 to 2.49). No association with the hormonal IUD, the oral pill, or the patch. It is a cross-sectional survey, so it captures associations. It does not establish causes.

Higgins and colleagues (2016) followed 159 of 200 enrolled women across three survey rounds, 20% copper IUD, 46% levonorgestrel IUD, 34% implant. Sexual functioning and satisfaction scores did not change over time. By three months, 40% reported positive changes to their sexual lives and 17% negative; the negatives were largely attributable to increased vaginal bleeding. Enzlin and colleagues (2012) compared 353 hormonal IUD users with 49 copper users, 402 of 845 invited returning the questionnaire. 33% of hormonal IUD users reported a sexual problem, versus 36.7% of copper users, with no significant difference; of those, 20% reported increased desire, 25% decreased, 5% excitement problems and 8% trouble finishing.

Hofmeyr and colleagues (2024) analyzed the ECHO trial, 7,829 women randomized to depot medroxyprogesterone, the copper IUD or the implant, with no hormonal IUD arm; decreased desire ran at 1.6% versus 1.1% versus 0.5%, from recall-based questionnaires. Dea and colleagues (2024) compared 315 women across methods; the hormonal group was younger, with lower satisfaction, reduced excitement, heightened pain, and higher anxiety and depression, while copper users had better sexual function than pill users. Age confounds that comparison, which is the caveat to hold. Our guide to birth control and low libido sorts the methods against each other.

The women who did feel a drop

If your drive is nowhere to be found, the surveys where women named the method match your experience. Malmborg and colleagues (2019) surveyed 153 intrauterine contraceptive users, 103 copper and 50 hormonal. 28% of hormonal IUD users reported a negative effect on sexual desire attributed to the method, versus 10.1% of copper users (p<0.05). Adjusted for age, body mass index, depression, parity, switching behaviour and partnership, the odds ran at 5.0 (95% CI 1.8 to 13.8). Self-reported attribution, no before-use baseline, wide confidence intervals: that is the strength of the number, and its limit.

Malmborg and colleagues (2016) posted a validated questionnaire to 3,740 young Swedish women, with a 50% response rate. 27% of hormonal contraceptive users reported a decrease in sexual desire attributed to their method, versus 12% of women using non-hormonal contraception (p<0.01). Multiple regression put the twofold risk independent of age group, depression, BMI, educational level and parity. Among women who had the same experience during a previous period of hormonal use, the odds of planning to stop or switch were 8.16 (95% CI 6.65 to 10.1). The hormonal group pools all hormonal methods, so IUDs are not isolated in that figure.

Ulubay and colleagues (2017) followed 36 women who scored in the dysfunction range and requested the levonorgestrel system; their total score rose from 19.3 to 21.1 at six months (p<0.001), a single centre with no control group, where a floor effect may explain the rise. Turan and colleagues (2021) tracked women with bleeding complaints before insertion: 12.5% scored 26.5 or above before, 52.5% after, again with no control group. So the before-after data lean the other way, and the honest read is that both directions happen. Two more reads: what HSDD actually means, and the birth-control sensation drop.

Two questions, two piles of evidence

When you ask whether Mirena (a levonorgestrel IUD) lowered your sex drive, you are really asking two different things at once. The first is what happens to the average woman over time: does her score move up, down, or stay put? The second is what happens to individuals: how many notice a drop, and how many do not? Those two questions pull in opposite directions, and the honest answer is that both are true at the same time. The pooled analyses say the average barely moves, while the self-reported surveys and the long phase 3 trial say a small minority do feel it.

What to bring to your clinician

Your clinician can only work with what you give them. Bring the right questions and the numbers that frame them, and the visit gets easier for both of you.

1. Which question you are asking: did the device do it, or is your drive coming back on its own?
2. The timeline: when the drop started, and how long since insertion.
3. The phase 3 minority figures, so your clinician can place your experience: trouble finishing and desire problems at 3.1% versus 1.4% at 360 days, split by prior contraception group.
4. The status of the pooled IUD analysis: no significant change through twelve months, with a wide interval that crosses zero.
5. The methods with a signal: the implant showed a positive change at six months, and the ECHO comparison ran across three methods with no hormonal IUD arm.
6. The supplement question, bottle in hand: NUUD does nothing for contraception, for hormones, or for the side effects of Mirena or any IUD or implant.

"I've tried everything"

If you have been through the methods, the timing, and the waiting, you have already done the hard part, which is noticing the change and naming it. What remains is the honest count of what has a signal behind it, because most of what the internet tells you does not.

Start with the strongest evidence. The only pooled analysis specific to progestin devices found no significant change for the hormonal IUD through twelve months, and a positive change for the implant at six months. That is the whole picture on averages: the IUD barely moves the needle, and the implant moved it the other way. Then come the self-reported surveys, where a minority of women said their desire dropped after switching to the hormonal IUD, with wide confidence intervals and no before-use baseline to lean on. And the cohorts split both ways: one large survey found no association between the hormonal IUD and lacking interest in sex, while a smaller prospective cohort found scores that did not change over time, with more women reporting improvements than declines.

So the honest count is this: the pooled data says the average barely moves, and the individual data says some people do feel a drop. Neither pile points at a single cause, and none of them measured the levers that were never in a trial. Sleep, load, and the relationship all flatten wanting in most people, and they sit outside every study in this set. If your numbers are fine and you still feel flat, numbers fine, still flat covers that. If stress is the thread running through it, stress, cortisol and sex drive covers that one.

The everyday levers, and where a botanical fits

NUUD does nothing for contraception, for hormones, or for the side effects of Mirena or any IUD or implant, and it has no role in managing any medical condition. Its own label carries a caution, quoted here word for word: avoid use if you are on blood pressure medication, have cardiovascular, renal, or pulmonary conditions, or if you are sensitive to any of the ingredients. For many readers of this article, that sentence is the answer. Talk to your clinician first and bring the label.

A few ordinary things move desire in most people, and the free ones do more work than the internet admits.

• Sleep, in quantity and quality, since a low drive and broken sleep feed each other. Sleep, libido and testosterone covers that.
• Movement you can sustain, something you will keep doing. Exercise and libido covers the wider picture.
• Treating the stress as the first lever, because a high load flattens wanting in most people before anything else does.
• Time with a partner, with nothing expected at the end.
• A botanical supplement, if you want one, as the smallest lever on the list.

NUUD is a botanical supplement built around desire in general. It does nothing for contraception, for hormones, or for the side effects of Mirena or any IUD or implant, and it has no role in managing any medical condition. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, and it works at roughly 30 to 60 minutes. If you take blood-pressure medication or have a heart, kidney or lung condition, the label says no, and your clinician decides the rest. If your clinician has read that label and has no objection, that is what our women's libido gummies are for. There is a men's version.

Nothing is wrong with you

The device is doing contraceptive work you cannot feel. That is the job you signed up for, and it is working. Wanting lives in a much wider system than that one small effect, and most of the time the device is only one thread in it. The numbers back that up in plain words: the pooled analysis of the hormonal IUD found no significant change in sexual-function scores through twelve months, and the long phase 3 trial logged trouble finishing and desire problems in a small minority of women. The average barely moves. A small minority feels a drop, and that is real too, even when the average does not move.

Stress, the cycle, and the life all flatten wanting in most people, and they do it quietly, without a lab result to point at. A heavy season, a low mood, a relationship in a lull, a body that is tired, a mind that is closed off, any of these can sit on top of the device and make it look like the device did it. None of them mean something is broken. They mean the system is busy with something else, and wanting is the first thing it lets go.

If you want to want it again, and you just want to feel normal again, start there. Name what is heavy, take care of the basics, and give it time. The device is doing its job. The wanting is not gone. It is waiting for the rest of the picture to settle.

Keep reading

• Our guide to birth control and low libido
• The birth-control sensation drop
• Sex drive and your menstrual cycle
• Low libido in women
• Why sex drive comes and goes
• Why is my libido so low?

Frequently asked questions

Does Mirena lower sex drive?
For the average woman, no. The only pooled analysis specific to progestin devices, nineteen studies covering 710 women, found no significant change in sexual-function scores with the hormonal IUD through twelve months, WMD 3.20, 95% CI -1.56 to 7.98. The interval is wide and crosses zero. A broader review of 9,427 women did find a lower desire subscale among contraceptive users overall, SMD -1.17, but it pooled every method, with very high heterogeneity, and it is never a Mirena figure.

Does the copper IUD affect sex drive?
The studies say no clear effect. One cross-sectional study found 33% of hormonal IUD users versus 36.7% of copper users reported a sexual problem, with no significant difference. A large survey found no association with the hormonal IUD, using copper users as the referent group at 18.3%. Another cross-sectional study found no significant difference in sexual function between copper and hormonal IUD users, and a prospective cohort found scores that did not change over time.

Does Nexplanon affect sex drive?
The evidence leans the other way. The pooled progestin-device analysis found a positive change for the implant at six months, WMD 3.48, 95% CI 2.78 to 4.19, p = .001. In the ECHO randomized trial of 7,829 women, which had no hormonal IUD arm, decreased desire was 0.5% for the implant versus 1.6% for DMPA. One cross-sectional study put 47.8% of implant users in the dysfunction range, with no significant difference between methods.

Will my sex drive come back after Mirena removal?
No study in this set tracked scores after removal, so nobody can promise it. The before-after studies showed scores rising after insertion, from 19.3±4.8 to 21.1±3.8, p<0.001, and the phase 3 trial reports 180-day and 360-day rates and nothing after removal. What you can do is tell your clinician what you are feeling, when it started, and how long it has lasted. That is the only honest starting point for the question.

Can I take a botanical supplement with an IUD?
Ask your clinician first, and bring the label. NUUD does nothing for contraception, for hormones, or for the side effects of Mirena or any IUD or implant, and it has no role in managing any medical condition. No interaction studies exist for this formula, so the decision is yours and your clinician's, based on the label caution and your own history.

References

1. Ghorbani M, Ashrafizaveh A, Azmoude E. Effects of progestin contraceptive methods on sexual function in reproductive age women: a meta-analysis. Journal of psychosomatic obstetrics and gynaecology. 2021;42(1):3-14. https://pubmed.ncbi.nlm.nih.gov/32048542/
2. Huang M, Li G, Liu J, Li Y, Du P. Is There an Association Between Contraception and Sexual Dysfunction in Women? A Systematic Review and Meta-analysis Based on Female Sexual Function Index. The journal of sexual medicine. 2020;17(10):1942-1955. https://pubmed.ncbi.nlm.nih.gov/32694069/
3. Ogle K, Handy AB. The Effects of Hormonal and Non-Hormonal Intrauterine Devices on Female Sexual Function: A Systematic Review. International journal of sexual health : official journal of the World Association for Sexual Health. 2023;35(1):67-81. https://pubmed.ncbi.nlm.nih.gov/38596762/
4. Kerns JL, Keder LM, Cwiak CA, Westhoff CL, Creinin MD. Hormone-related side effects in new users of a levonorgestrel 52-mg intrauterine device. American journal of obstetrics and gynecology. 2024;231(6):628.e1-628.e10. https://pubmed.ncbi.nlm.nih.gov/38969201/
5. Boozalis A, Tutlam NT, Chrisman Robbins C, Peipert JF. Sexual Desire and Hormonal Contraception. Obstetrics and gynecology. 2016;127(3):563-572. https://pubmed.ncbi.nlm.nih.gov/26855094/
6. Higgins JA, Sanders JN, Palta M, Turok DK. Women's Sexual Function, Satisfaction, and Perceptions After Starting Long-Acting Reversible Contracepts. Obstetrics and gynecology. 2016;128(5):1143-1151. https://pubmed.ncbi.nlm.nih.gov/27741195/
7. Enzlin P, Weyers S, Janssens D, Poppe W, Eelen C, Pazmany E, et al. Sexual functioning in women using levonorgestrel-releasing intrauterine systems as compared to copper intrauterine devices. The journal of sexual medicine. 2012;9(4):1065-73. https://pubmed.ncbi.nlm.nih.gov/21492401/
8. Hofmeyr GJ, Singata-Madliki M, Batting J, Steyn P, Thomas KK, Issema R, et al. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial. PloS one. 2024;19(5):e0299802. https://pubmed.ncbi.nlm.nih.gov/38722832/
9. Singata-Madliki M, Carayon-Lefebvre d'Hellencourt F, Lawrie TA, Balakrishna Y, Hofmeyr GJ. Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2021;154(2):256-262. https://pubmed.ncbi.nlm.nih.gov/33448029/
10. Déa CA, Moreira ECH, Zamboti CL. Sexual function, quality of life, anxiety, and depression in women of reproductive age using hormonal, nonhormonal, and no contraceptive methods. The journal of sexual medicine. 2024;21(8):683-690. https://pubmed.ncbi.nlm.nih.gov/38842258/
11. Malmborg A, Brynhildsen J, Hammar M. A survey of young women's perceptions of the influence of the Levonorgestrel-Intrauterine System or copper-intrauterine device on sexual desire. Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives. 2019;21:75-80. https://pubmed.ncbi.nlm.nih.gov/31395237/
12. Malmborg A, Persson E, Brynhildsen J, Hammar M. Hormonal contraception and sexual desire: A questionnaire-based study of young Swedish women. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. 2016;21(2):158-67. https://pubmed.ncbi.nlm.nih.gov/26406399/
13. Ulubay M, Ozturk M, Firatligil FB, Fidan U, Karaca RE, Yenen MC. Effects of Levonorgestrel Intrauterine System on Patients with Female Sexual Dysfunction. The Journal of reproductive medicine. 2017;62(1-2):26-30. https://pubmed.ncbi.nlm.nih.gov/29999278/
14. Turan G, Yalcin Bahat P, Aslan Cetin B, Peker N. The effect of a levonorgestrel-releasing intrauterine device on female sexual function. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2021;41(2):269-274. https://pubmed.ncbi.nlm.nih.gov/32498582/
15. Ferreira JM, Carreiro AV, Fernandes A, Bahamondes L. Sexual Function and Quality of Life in a Cohort of Brazilian Users of Two Kind of Intrauterine Contracepts. Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia. 2019;41(4):236-241. https://pubmed.ncbi.nlm.nih.gov/30912090/
16. Koseoglu SB, Deveer R, Akin MN, Gurbuz AS, Kasap B, Guvey H. Is There Any Impact of Copper Intrauterine Device on Female Sexual Functioning? Journal of clinical and diagnostic research : JCDR. 2016;10(10):QC21-QC23. https://pubmed.ncbi.nlm.nih.gov/27891404/
17. Sakinci M, Ercan CM, Olgan S, Coksuer H, Karasahin KE, Kuru O. Comparative analysis of copper intrauterine device impact on female sexual dysfunction subtypes. Taiwanese journal of obstetrics & gynecology. 2016;55(1):30-4. https://pubmed.ncbi.nlm.nih.gov/26927244/
18. Trigo ACM, Maron CC, Pinheiro MSA, da Silva SBL, Brito MB. Female sexual function in women using LARC methods. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2022;38(1):68-72. https://pubmed.ncbi.nlm.nih.gov/34672861/
19. Ye S, Ma L, Huang Y, Su B, Cao Y, Huang J, et al. Effect of different long-acting reversible contraceptive methods on female sexual function: a retrospective cohort study. BMC women's health. 2026;26(1):. https://pubmed.ncbi.nlm.nih.gov/42277791/
20. Both S, Lew-Starowicz M, Luria M, Sartorius G, Maseroli E, Tripodi F, et al. Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). The journal of sexual medicine. 2019;16(11):1681-1695. https://pubmed.ncbi.nlm.nih.gov/31521571/

This article is for general education and is not medical advice. Mirena (a levonorgestrel IUD) is a prescription device, and contraception is prescribed and managed by a licensed clinician. NUUD is a botanical supplement and has no role in diagnosing, treating, curing, or preventing any hormonal condition, the side effects of any contraceptive, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your clinician before starting any new supplement, and do not remove or change your contraception without your clinician.